FierceBiotechOriginal article
{"a":[{"_":"Vertex’s midstage data amplify kidney disease market opportunity","$":{"href":"/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity","hreflang":"en"}}]}
Phase 2positiveinaxaplinPositive
AI Analysis
Summary
Vertex reported positive phase 2b data for inaxaplin in kidney disease, expanding the market opportunity beyond the population targeted in its pivotal trial.
Clinical Trial Data
Phase
2b
Primary Endpoint
Met
Outcome Details
Phase 2b data reported for inaxaplin in kidney disease
Importance:6/10
Sentiment:
0.70
Phase 2bkidney diseaseclinical trialpositive data
Related Companies
Read the original article
Published by FierceBiotech on September 22, 2026 10:10 AM